Back to top

Zacks Industry Rank Analysis

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

It seems every ailment has a cure and every cure, an ailment.  Browsing the drug store, you can’t help but feel like “there’s a pill for that,” as prescribed by Dr. Siri.  On the other hand, side effects need to be monitored closely.  One could draw a similar parallel to investing in pharmaceuticals.

The Medical/Drugs sector of the Zacks Industry Rank list gained 33 positions last week -- significant movement for a sector comprised of 97 companies.  After this booster, the industry now holds a rank of #56 out of 260 ranked industries.  With positive earnings revisions outpacing negative 143 to 74, the average positive Earnings per Share (EPS) surprise of +10% is remarkable given the size of the sector.

Two of the biotech and pharmaceutical companies have a particularly positive prognosis, moving last week to a Zacks Rank #1 (Strong Buy) from a “Buy” or “Hold” rating.  This could signal positive future performance for these stocks in response to future positive earnings estimate revisions.  While a good indicator of industry health, it’s equally important to understand the fine-print details when mixing with other investments.

Take a look at the following companies and see if they could give your portfolio a needed shot in the arm.

Enanta Pharmaceuticals Inc. (ENTA - Snapshot Report)

ENTA was upgraded to a Zacks Rank #1 (Strong Buy) last week from #3 (Neutral).
 
Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as the hepatitis C virus, respiratory tract infections, intravenous and oral treatments.  Consider its strong position in royalties on sales of ABT-450, its low-cost profile could be just the ticket for continued profitability.

Its last earnings surprise was +30%.

Sucampo Pharmaceuticals (SCMP - Snapshot Report)

SCMP is a Zacks Rank #1 (Strong Buy).  It moved up from a Zacks Rank #2 (Buy) last week.  

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.

Sucampo’s last earnings surprise was +400%.  2014 consensus EPS estimates are still drifting higher. This company reports quarterly earnings on March 12, 2014.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%